Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b randomized, ...
On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...
Alto Neuroscience Inc. (NYSE:ANRO) is one of the best IPO stocks to buy according to Wall Street analysts. On June 26, Alto Neuroscience announced positive pharmacodynamic results from an exploratory ...
– Successful outcome from recent FDA meeting guides Alto’s plan to accelerate development of ALTO-207, with capital from a $50 million private placement financing expected to enable the company to ...
– ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – ...
– Issued and pending claims expected to protect ALTO-207 into the mid-2040s – MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical ...
Zacks Investment Research on MSN
Will AbbVie's neuroscience franchise aid top-line growth in Q1?
AbbVie ABBV is set to report first-quarter 2026 results on April 29. While the company’s immunology portfolio will remain the ...
A large twin study found that adverse childhood experiences increase the risk of developing treatment-resistant depression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results